



"Here, the implant is not fully reimbursed. There is problem with pricing of the glaucoma implants."  
Ophthalmologist and owner of a leading ophthalmological clinic

## Payment mechanism

### Drug treatment the 1st line treatment

1. monotherapy
2. fixed combinations



- Prostaglandin analogs (26%)
- Inhibitors of Carboanhydrasis (26%)
- Betablockers (8.5%)
- other (39.5%)



Usually completely reimbursed from Health Insurance Company


### Laser iridotomy the 2nd line treatment

Treatment phase	Payment mechanism
Pre-operative treatment	fully reimbursed
Laser surgery	fully reimbursed
Post operative control (1)	partly reimbursed + copayment 50 EUR

### Trabeculectomy (surgery) the 3rd line treatment

Treatment phase	Payment mechanism
Pre-operative treatment	fully reimbursed
Surgery + implant	partly reimbursed + copayment 50 EUR
Post operative control (3)	fully reimbursed

People who received services for glaucoma



Source: NCZI

The incidence of primary glaucoma is around **18 000 annually**

reimbursement for surgery

Year	Laser surgery	Filtration surgery
2012	250 EUR	350 EUR
2013	260 EUR	360 EUR
2014	260 EUR	360 EUR
2015	260 EUR	360 EUR
2016	266 EUR	365 EUR
2017	271 EUR	370 EUR
2018	271 EUR	370 EUR
2019	271 EUR	370 EUR
2020	271 EUR	370 EUR

Source: provider contracts with health insurance companies, 2020



## Good practice

- Reimbursement of a wide range of pharmaceuticals



## Room for improvement

- The price implant is not fully reimbursed

Access to healthcare services in the context of financing mechanisms. The case of ophthalmology



Start: 01-11-2021  
End: 30-04-2023  
Project ID: Ns22120107  
Programme: Visegrad Fund